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Abstract
Very little guidance exists to help
clinicians and families decide whether
mammograms are useful in elderly
women with Alzheimer’s Disease (AD).
We present a case of a patient with
moderate AD who had a positive
mammogram and discuss the dilemma
faced by the family and clinician in
deciding what was best to do for the
patient. In this case, the family opted for
breast conserving surgery (BCS) followed
by palliative care which brought up the
question of whether screening was
appropriate with this treatment goal in
mind. We reviewed the literature on AD
and breast cancer screening and
summarize these findings in our
discussion.

Introduction
Alzheimer’s Disease (AD) is
the sixth leading cause of death in
the United States with a current
prevalence of about 5.4 million
Americans and expected to rise
to 16 million by the year 2050. In
2011, nearly $183 billion was spent
on health care, long term care,
and hospice care costs for people

with AD and other dementias.1
Few articles exist that help guide
clinicians on whether screening
mammograms would benefit patients
with AD. We present the case of
a patient with moderate AD who
continued to receive mammograms
and the lesson learned from this
case when it became evident that
the family did not want aggressive
treatment of the patient’s cancer.

Case presentation
An 82-year-old female presented
with memory loss at age 75 and
her mini-mental status at that time
was 29/30 (normal 26-30). She had
a gradual loss of memory over the
ensuing 7 years and was diagnosed
with AD. At age 82 she was
ambulating without assistance and,
aside from a history of osteoporosis,
she had no other medical problems.
She continued to have regular
preventive care including yearly
mammograms, but a dilemma arose
when her mammogram showed a 14
mm lesion in the left breast highly
suspicious for cancer. Unfortunately,
her memory had declined to a minimental status score of 19 consistent
with moderate dementia and she
was unable to make decisions for
herself. After discussion with the
family, the patient was referred
to a surgeon and a lumpectomy

was performed which revealed a
1.3 cm grade 1 infiltrating lobular
carcinoma that was completely
excised. The tumor was ER positive,
PR negative and Her2 negative.
At this point the family decided
not to put the patient through any
more treatment. She lived two
more years and over that time had
a gradual decline in her functional
status and memory, eventually
becoming bedfast and requiring
nursing home care before she died.

Discussion
This 82-year-old patient with
moderate AD continued to receive
breast cancer screening which
may not have been appropriate.
Some may argue that even healthy
82–year-old women should not
receive breast cancer screening. The
US Preventive Services Task Force
(USPSTF) concluded that evidence as
to whether breast cancer screening
for women 75 years or older has any
benefit is lacking since randomized
controlled trials of breast cancer
screening did not include this age
group.2 The American Geriatric
Society Clinical Practice Committee
recommends biennial or every three
year screening for women over
age 75 years as long as their life
expectancy is at least four years.3
The Cochrane review analysis of
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seven randomized trials comparing
screening mammography versus
no screening revealed three well
designed trials which did not show
any significant decrease in breast
cancer mortality and four less
optimally designed trials showing a
significant decrease in breast cancer
mortality.4 The overall evidence for a
benefit of screening mammography
in women over age 75 is not clear.
The ethical dilemma of whether
or not to recommend screening
mammography among AD patients
has been discussed by Raik et
al.5 They considered the benefits
such as improved survival from
early detection and treatment, and
reassurance of negative examination,
which will possibly benefit
mildly impaired patients, but not
moderately or severely demented
patients who may not understand
the reassurance of a negative scan.

The burdens of mammography
can be due to overdiagnosis with
false positive screening results
leading to diagnostic mammograms
and biopsies or overtreatment
of premalignant conditions such
as ductal carcinoma in situ.
Additional harm may occur from
subjecting cognitively impaired
patients to a procedure that they
do not understand. Raik et al
suggested withholding screening
mammography for patients with
advanced dementia, significant
comorbidity, or a life expectancy of
less than 5 years. However, patients
with mild dementia who may have
the capability to understand benefits
and harms should be given the
opportunity to decide for themselves
about screening after a discussion
with their primary care provider.
When considering breast cancer
screening in patients with AD, the

goals of care for the individual
patient should be discussed. Goals
of care have been classified by
Sachs into prolongation of life,
some limitations on life prolonging
treatment weighing treatment
benefits and burdens, and palliation.6
Although for most people, including
many AD patients, life prolongation
is the major goal, this may change
as the disease progresses. Cassel
suggested that a good rule to follow
would be that if surgery would
be performed should a lump be
discovered then mammography
should be continued.7 A study about
the importance of screening for
breast cancer involving 23 caregivers
of women with dementia revealed
that most caregivers of women with
mild to moderate dementia have the
intent to continue screening, while
caregivers of women with severe
dementia did not perceive screening
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as important.8 Moreover, similar to
the family in our case, their opinions
on appropriate treatment if the
patient with AD developed breast
cancer was toward non-aggressive or
comfort care. Unfortunately, families
often schedule the mammogram
without discussing it first with the
primary care provider. In order
to avoid being surprised with
the dilemma of dealing with an
abnormal mammogram in a patient
with AD whose goal is palliation,
preemptive discussion about the
appropriateness of continuing
screening mammography needs
to take place at least annually.
Older women with a life
expectancy of less than five years are
less likely to benefit from screening
mammography. A study of the
impact of cognitive impairment on
screening mammography found
that although women with severe
cognitive impairment have a lower
rate of mammogram utilization
compared to women without
cognitive impairment, an estimated
120,000 screening mammograms
were performed among women
with severe cognitive impairment,
a group with a median survival of
just 3.3 years.9 This represents a
use of medical resources that may
not be having much benefit. Larson
et al10 showed that unsteady gait,
wandering, incontinence of urine,
low score on mini-mental status exam
at presentation or drop of 5 points
in first year, and pre-existing heart
disease or diabetes predict shorter
life expectancy among patients with
AD. Physicians need to be aware of
factors causing shortened survival
in AD so they can better advise
their patients and families on the
merits of breast cancer screening.
Our patient’s family opted for
breast conserving surgery (BCS)
alone as treatment for her early stage
breast cancer. This is a fairly common
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choice according to a cohort study of
50,460 breast cancer patients of whom
1,935 patients had a diagnosis of AD
which concluded that women with
AD more often chose BCS than those
without AD.11 Moreover, the AD
patients were less likely to receive
any treatment for their breast cancer.
Different treatment modalities
among patients over age 70 years
with early stage breast cancer have
been discussed by the International
Society of Geriatric Oncology.12 BCS is
currently preferred over mastectomy
especially in the elderly as it may
lead to a better quality of life with
no difference in overall survival or
disease-free survival compared to
total mastectomy, however local
recurrence is increased with BCS
alone. Radiotherapy reduces local
recurrence rate, however, there is
controversy in its overall survival
benefits. Patient’s health status,
functional capacity, comorbidities,
and risk of local recurrence should
be considered before offering
radiotherapy. Adjuvant hormonal
therapy with either tamoxifen or
aromatase inhibitors typically will
benefit older patients with hormone
sensitive breast cancers. The decision
to give adjuvant chemotherapy
should include consideration
of absolute benefits, individual
patient tolerance, life expectancy,
and other comorbidities.11
In conclusion, screening
mammograms should not be used
in severely demented patients.
Those with mild or moderate AD
should decide about screening based
on comorbidities, life expectancy,
and intent to treat the cancer once
discovered. Healthcare providers
of patients with AD should have
periodic discussions regarding
the appropriateness of screening
mammograms as the disease
progresses and goals of care change.
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CME Post-Test
37.	Regarding the evidence for screening
mammograms for women over age 75 years:
a. The USPSTF states that screening is definitely
indicated and supported by evidence.
b. The American Geriatrics Society states that
mammograms could be offered every 2-3 years in
the elderly with at least 4 years of life expectancy.
c. Most clinical trials of screening mammography
included women over age 75.
d. T
 he best designed clinical trials showed
a decrease in breast cancer mortality.
38.	According to Raik et al, which of the
following was appropriate:
a. Mammograms should be withheld from patients
with less than 10 years life expectancy

b. Patients with mild to moderate dementia would
not benefit from screening mammograms
c. Patients with severe dementia would not
benefit from reassurance of a negative exam.
d. One of the burdens of mammography
is the cost to the patient.
39.	Regarding treatment of breast cancer
in Alzheimer’s disease
a. T
 otal mastectomy is preferred by most patients.
b. Radiation therapy helps prevent
distant metastasis.
c. Hormonal therapies are rarely used in the elderly.
d. Breast conserving therapy for early stage
disease has no difference in survival
compared to total mastectomy.
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